Top 10 Books about Stock Investing to read in 2018. Read more.

BSPM - Biostar Pharmaceuticals

Industry: Drug Manufacturers - Major Sector: Healthcare Exchange: NASDAQ

BSPM - Biostar Pharmaceuticals

Industry: Drug Manufacturers - Major Sector: Healthcare Exchange: NASDAQ

Fri 16'th Feb 2018

PERIOD 2017-11-17 - 2018-02-16
CHANGE -5.16%
PRICE $3.86






Biostar Pharmaceuticals Stock Analysis

Technical stock analysis for Fri 16'th Feb 2018

Shorts 0.07% ( 2018-01-31 )
Cash n/a
Loans n/a
Beta 2.00
ROA 2.23
Buy candidate since 2018-01-03 Gain 103.22%

Biostar Pharmaceuticals fell by -5.16% in the last day from $4.07 to $3.86 and has now fallen 3 days in a row. The price has fallen in 6 of the last 10 days and is down by -3.98% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -191 306 shares and in total 261 984 shares bought and sold for approximately $1.01 million.

Access today's Top 5 Buy Candidates


Biostar Pharmaceuticals lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 105.4% during the next 3 months and, with 90% probability hold a price between $6.33 and $9.71 at the end of this period.

Click here for today's Top 5 Trending Companies


Biostar Pharmaceuticals holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $4.37. On a fall, the stock will find some support from the long-term average at approximately $2.85. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Wednesday February 14, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 62 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $3.60 and $3.32. On the upside the stock meets some resistance just above today's level from accumulated volume at $4.02, $4.26 and $4.62.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Biostar Pharmaceuticals finds support just below today's level at $3.60. If this is broken, then the next support from accumulated volume will be at $3.32 and $2.90. The stock is about to test the resistance from accumulated volume at $4.02 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Support: $3.60 Price: $3.86 Resistance: $4.02


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.39 between high and low, or 10.37%. For the last week the stock has had a daily average volatility of 12.00%.

Our recommended stoploss: $3.48 (-9.85%) (This stock has very high daily movements and this gives very high risk. There is a sell signal from pivot top found 2 days ago.)

Overall risk:

Very Low Low Medium High Very High


Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term.

Trade BSPM CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).